ACCESS Newswire

Cannabis Suisse Corp

15.7.2021 14:02:27 CEST | ACCESS Newswire | Press release

Share
Cannabis Suisse Corp. Announces the Results of Laboratory Testing of Its New Product Line and Creation the "LEARN" Section on the Website

DIETIKON, SWITZERLAND / ACCESSWIRE / July 15, 2021 / Cannabis Suisse Corp. (OTC PINK:CSUI), a Nevada incorporated distribution company for recreational cannabis products and CBD oils, announces the results of laboratory testing of its new product line created for the upcoming launch on Shopify.

This news follows a recent announcement on the decision to choose ACS Laboratory as a CBD laboratory for testing the first shipment of the new Swiss4Life CBD brand, created for the launch of an online store on Shopify platform. The samples of products were sent to ACS laboratory to obtain СOA proving the quality of the new brand name CBD oils to the potential customers.

The certificates are ready for all the six types of current products: THC Free CBD Oil (Cherry Vanilla and Creme de Menthe) and CBD Tinctures with different therapeutic effects.

THC Free CBD Oil 1500 mg Cherry Vanilla has 1,521.586mg of Cannabinoids total (5.376%). 5.096% (1,442.211mg) are represented by CBD, 0.131% (36.992mg) are CBG, 0.051% (14.474mg) are CBN. The number of other Cannabinoids is 0.099% (27.909mg). THC is not detected.

THC Free CBD Oil 2500 mg Creme de Menthe contains 2,458.295mg of Cannabinoids total (8.654%). 8.177% (2,322.842mg) are represented by CBD, 0.209% (59.457mg) are CBG, 0.098% (27.851mg) are CBN. The number of other Cannabinoids is 0.169% (48.145mg). THC is not detected.

THC Free CBD Oil 3500 mg Cherry Vanilla has 3,513.119mg of Cannabinoids total (12.299%). 11.770% (3,362.096mg) are represented by CBD, 0.275% (78.554mg) are CBG, 0.115% (32.821mg) are CBN. The number of other Cannabinoids is 0.139% (39.648mg). THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Focus contains 934.326mg of Cannabinoids total (3.328%). 3.314% (930.404mg) are represented by CBD, THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Anti-Stress Formula has 920.788mg of Cannabinoids total (3.652%). 3.632% (915.728mg) are represented by CBD, THC is not detected.

CBD TINCTURES Natural Sleep Formula contains 913.149mg of Cannabinoids total (3.331%). 3.331% (913.149mg) are represented by CBD, other Cannabinoids or THC are not detected.

Since the Company received the certificates of analysis, a special page has been created on the site in the "LEARN" section so that users can see them at any time on their own and make sure of their authenticity. The COA were uploaded there along with the testing date.

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a public US Company incorporated in Nevada state. The Company operates in the field of distribution of recreational cannabis products and CBD oils. Cannabis Suisse Corp. currently sells via a distribution network of retailers and online shops, under the retail brand Swiss4Life. Swiss4Life products are made of USA hemp only and contain no THC, GMO or Gluten. They have not been evaluated by the FDA and are not designated for medical use. However, all the products available are manufactured by FDA Registered Entities and tested by independent third-party laboratories. Cannabis Suisse Corp's products are laboratory tested to ensure the end-users have access to a standardized, safe, and consistent product.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that

are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

CONTACT:

Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz

SOURCE: Cannabis Suisse Corp.



View source version on accesswire.com:
https://www.accesswire.com/655563/Cannabis-Suisse-Corp-Announces-the-Results-of-Laboratory-Testing-of-Its-New-Product-Line-and-Creation-the-LEARN-Section-on-the-Website

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release

PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this

Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release

New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m

Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release

TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block

IXOPAY Appoints Ajoy Krishnamoorthy as CEO to Accelerate Growth and Advance Payments for the Agentic Age25.8.2026 12:00:00 CEST | Press release

Enterprise Software and Commerce Leader Will Guide IXOPAY's Next Development Phase of Its Unified, AI-Native Payments Infrastructure Platform DALLAS, TX / ACCESS Newswire / August 25, 2026 / IXOPAY, the payment infrastructure solution that enables fluid commerce, today announced the appointment of Ajoy Krishnamoorthy as CEO. Krishnamoorthy brings more than two decades of enterprise software leadership and extensive product engineering experience turning complex technologies into platforms that businesses depend on to grow. Krishnamoorthy joins IXOPAY at a pivotal moment, as it helps unlock fluid commerce for enterprise merchants. Krishnamoorthy will focus on bringing IXOPAY's modular product suite into the agentic age, providing merchants with the freedom to buy what they need and build what they want in scaling their global payment operations. He comes with a customer-first mindset, ensuring momentum is maintained, and support is given to customers during this seismic shift in the lan

LiberNovo Support Week Goes Live: Up to 44% Off on Maxis, Omni SE and Omni Pro Ergonomic Chair Series25.8.2026 09:00:00 CEST | Press release

HONG KONG, HK / ACCESS Newswire / August 25, 2026 / LiberNovo Support Week is now open across the European Union and the United Kingdom. Through September 8, the Maxis Series, Omni SE, and Omni Pro are up to 44% off in the EU and up to 39% off in the UK, with three gift tiers and triple points for members. The name works two ways. Support your body. LiberNovo chairs respond as you lean in, sit upright, and recline, instead of holding you to one fixed posture. Support your journey. Through Create for Creators, LiberNovo backs the developers, designers, streamers, and gamers who do their work seated. Maxis Series: Built for Bigger Builds The event leads with the Maxis Series, sized from the frame up for taller, broader, and heavier users. A 52 cm seat depth supports more of the thigh, the wider cushion leaves room to shift, and the reinforced structure is rated to 181 kg. Five-stage recline control runs from 105° to 160° on progressive springs, so support holds steady at every angle, inc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye